Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 1, 2013, Pages 89-103

  Soto Pantoja, David R ^a   Stein, Erica V ^a   Rogers, Natasha M ^b   Sharifi Sanjani, Maryam ^b   Isenberg, Jeffrey S ^b   Roberts, David D ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Autophagy; Cancer immunotherapy; Ionizing radiation; Ischemia; Macrophages; Nitric oxide; Reperfusion injury; Thrombospondin 1; Tissue perfusion

Indexed keywords

ANTIBODY; CD47 ANTIBODY; CD47 ANTIGEN; LIGAND; LIGAND SIRP ALPHA; MORPHOLINO OLIGONUCLEOTIDE; THROMBOSPONDIN 1; UNCLASSIFIED DRUG;

AGING; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTERY TONE; BIOCOMPATIBILITY; BLOOD FLOW; BLOOD PRESSURE REGULATION; CANCER GROWTH; CARDIOVASCULAR SYSTEM; CELL DEATH; CELL STRESS; CELL SURVIVAL; DIABETES MELLITUS; DRUG TARGETING; EFFECTOR CELL; HEART VENTRICLE HYPERTROPHY; HUMAN; IMMUNE EVASION; IMMUNE SYSTEM; INFLAMMATION; INFLAMMATORY DISEASE; INNATE IMMUNITY; ISCHEMIA; LEUKOCYTE MIGRATION; LYMPHOCYTE DIFFERENTIATION; MOLECULAR INTERACTION; NEOPLASM; NONHUMAN; ORGAN TRANSPLANTATION; PATHOPHYSIOLOGY; PLASTIC SURGERY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PULMONARY HYPERTENSION; RADIATION INJURY; RADIATION PROTECTION; REGULATORY MECHANISM; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TISSUE ENGINEERING; TISSUE SURVIVAL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; VASCULAR DISEASE; WOUND HEALING;

ANIMALS; ANTIGENS, CD47; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84871217458     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.733699     Document Type: Review

References (141)

1. Miller YE, Daniels GL, Jones C, et al. Identification of a cell-surface antigen produced by a gene on human chromosome 3 (cen-q22) and not expressed by Rhnull cells. Am J Hum Genet 1987;41:1061-70 (Pubitemid 18036005)
2. Frazier WA, Isenberg JS, Kaur S, et al. CD47. UCSD Nat Mol Pages 2010;doi:10.1038/mp.a002870.01 http://www.signaling-gateway.org/ molecule/query?afcsid=A002870
3. Lindberg FP, Lublin DM, Telen MJ, et al. Rh-related antigen CD47 is the signal-transducer integrin-associated protein. J Biol Chem 1994;269:1567-70 (Pubitemid 24035337)
4. Poels LG, Peters D, van Megen Y, et al. Monoclonal antibody against human ovarian tumor-associated antigens. J Natl Cancer Inst 1986;76:781-91 (Pubitemid 16121933)
5. Tsai RK, Rodriguez PL, Discher DE. Self inhibition of phagocytosis: The affinity of 'marker of self' CD47 for SIRPalpha dictates potency of inhibition but only at low expression levels. Blood Cells Mol Dis 2010;45:67-74
6. Oldenborg PA, Zheleznyak A, Fang YF, et al. Role of CD47 as a marker of self on red blood cells. Science 2000;288:2051-4 (Pubitemid 30397687)
7. Burger P, Hilarius-Stokman P, de Korte D, et al. CD47 functions as a molecular switch for erythrocyte phagocytosis. Blood 2012;119:5512-21
8. Chao MP, Jaiswal S, Weissman-Tsukamoto R, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2010;2:63ra94
9. Roberts DD, Miller TW, Rogers NM, et al. The matricellular protein thrombospondin-1 globally regulates cardiovascular function and responses to stress. Matrix Biol 2012;31:162-9
10. Kaur S, Kuznetsova SA, Pendrak ML, et al. Heparan sulfate modification of the transmembrane receptor CD47 is necessary for inhibition of T cell receptor signaling by thrombospondin-1. J Biol Chem 2011;286:14991-5002
11. Maile LA, Capps BE, Miller EC, et al. Glucose regulation of integrin-associated protein cleavage controls the response of vascular smooth muscle cells to insulin-like growth factor-I. Mol Endocrinol 2008;22:1226-37 (Pubitemid 351629621)
12. Allen LB, Capps BE, Miller EC, et al. Glucose-oxidized low-density lipoproteins enhance insulin-like growth factor I-stimulated smooth muscle cell proliferation by inhibiting integrin-associated protein cleavage. Endocrinology 2009;150:1321-9
13. Reinhold MI, Lindberg FP, Plas D, et al. In vivo expression of alternatively spliced forms of integrin-associated protein (CD47). J Cell Sci 1995;108:3419-25
14. Van Niekerk CC, Ramaekers FC, Hanselaar AG, et al. Changes in expression of differentiation markers between normal ovarian cells and derived tumors. Am J Pathol 1993;142:157-77 (Pubitemid 23026920)
15. Buist MR, Kenemans P, Molthoff CF, et al. Tumor uptake of intravenously administered radiolabeled antibodies in ovarian carcinoma patients in relation to antigen expression and other tumor characteristics. Int J Cancer 1995;64:92-8
16. Nishiyama Y, Tanaka T, Naitoh H, et al. Overexpression of integrin-associated protein (CD47) in rat kidney treated with a renal carcinogen, ferric nitrilotriacetate. Jpn J Cancer Res 1997;88:120-8 (Pubitemid 27129638)
17. Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009;138:286-99
18. Willingham SB, Volkmer JP, Gentles AJ, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 2012;17:6662-7
19. Suzuki S, Yokobori T, Tanaka N, et al. CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma. Oncol Rep 2012;28:465-72
20. Jaiswal S, Jamieson CH, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009;138:271-85
21. Bauer PM, Bauer EM, Rogers NM, et al. Activated CD47 promotes pulmonary arterial hypertension through targeting caveolin-1. Cardiovasc Res 2012;93:682-93
22. Rogers NM, Thomson AW, senberg JS. Activation of parenchymal CD47 promotes renal ischemia-reperfusion injury. J Am Soc Nephrol 2012; In press . Demonstrated therapeutic benefits of CD47-blocking antibody in a kidney transplant model.
23. Khandelwal S, van Rooijen N, Saxena RK. Reduced expression of CD47 during murine red blood cell (RBC) senescence and its role in RBCclearance from the circulation. Transfusion 2007;47:1725-32 (Pubitemid 47300620)
24. Olsson M, Oldenborg PA. CD47 on experimentally senescent murine RBCs inhibits phagocytosis following Fcgamma receptor-mediated but not scavenger receptor-mediated recognition by macrophages. Blood 2008;112:4259-67
25. Odievre MH, Bony V, Benkerrou M, et al. Modulation of erythroid adhesion receptor expression by hydroxyurea in children with sickle cell disease. Haematologica 2008;93:502-10
26. Chang WT, Chen HI, Chiou RJ, et al. A novel function of transcription factor alpha-Pal/NRF-1: increasing neurite outgrowth. Biochem Biophys Res Commun 2005;334:199-206
27. Gao AG, Lindberg FP, Dimitry JM, et al. Thrombospondin modulates alphav-3 function through integrin-associated protein. J Cell Biol 1996;135:533-44 (Pubitemid 26359345)
28. N'Diaye EN, Brown EJ. The ubiquitin-related protein PLIC-1 regulates heterotrimeric G protein function through association with Gbetagamma. J Cell Biol 2003;163:1157-65 (Pubitemid 37541890)
29. Frazier WA, Gao A-G, Dimitry J, et al. The thrombospondin receptor integrin-associated protein (CD47) functionally couples to heterotrimeric Gi. J. Biol. Chem 1999;274:8554-60 (Pubitemid 29164646)
30. Sick E, Niederhoffer N, Takeda K, et al. Activation of CD47 receptors causes histamine secretion from mast cells. Cell Mol Life Sci 2009;66:1271-82
31. Manna PP, Frazier WA. The mechanism of CD47-dependent killing of T cells: heterotrimeric Gi-dependent inhibition of protein kinase A. J Immunol 2003;170:3544-53 (Pubitemid 36359221)
32. Lamy L, Ticchioni M, Rouquette-Jazdanian AK, et al. CD47 and the 19 kDa interacting protein-3 (BNIP3) in T cell apoptosis. J Biol Chem 2003;278:23915-21 (Pubitemid 36830219)
33. Zhang J, Ney PA. Role of BNIP3 and NIX in cell death, autophagy, and mitophagy. Cell Death Differ 2009;16:939-46
34. Bras M, Yuste VJ, Roue G, et al. Drp1 mediates caspase-independent type III cell death in normal and leukemic cells. Mol Cell Biol 2007;27:7073-88 (Pubitemid 47549746)
35. Kaur S, Martin-Manso G, Pendrak ML, et al. Thrombospondin-1 inhibits vascular endothelial growth factor receptor-2 signaling by disrupting its association with CD47. J Biol Chem 2010;285:38923-32
36. Bauer EM, Qin Y, Miller TW, et al. Thrombospondin-1 supports blood pressure by limiting eNOS activation and endothelial-dependent vasorelaxation. Cardiovasc Res 2010;88:471-81
37. Isenberg JS, Shiva S, Gladwin M. Thrombospondin-1-CD47 blockade and exogenous nitrite enhance ischemic tissue survival, blood flow and angiogenesis via coupled NO-cGMP pathway activation. Nitric Oxide 2009;21:52-62
38. Isenberg JS, Ridnour LA, Dimitry J, et al. CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem 2006;281:26069-80 (Pubitemid 44401813)
39. Miller TW, Isenberg JS, Roberts DD. Thrombospondin-1 is an inhibitor of pharmacological activation of soluble guanylate cyclase. Br J Pharmacol 2010;159:1542-7
40. Ramanathan S, Mazzalupo S, Boitano S, et al. Thrombospondin-1 and angiotensin II inhibit soluble guanylyl cyclase through an increase in intracellular calcium concentration. Biochemistry 2011;50:7787-99
41. Isenberg JS, Romeo MJ, Yu C, et al. Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/ cGMP signaling. Blood 2008;111:613-23
42. Isenberg JS, Hyodo F, Pappan LK, et al. Blocking thrombospondin-1/ CD47 signaling alleviates deleterious effects of aging on tissue responses to ischemia. Arterioscler Thromb Vasc Biol 2007;27:2582-8 (Pubitemid 350158909)
43. Rogers NM, Roberts DD, Isenberg JS. Age-associated induction of cell membrane CD47 limits basal and temperature-induced changes in cutaneous blood flow. Ann Surg 2012; In press
44. Yao M, Roberts DD, Isenberg JS. Thrombospondin-1 inhibition of vascular smooth muscle cell responses occurs via modulation of both cAMP and cGMP. Pharmacol Res 2011;63:13-22
45. Isenberg JS, Maxhimer JB, Hyodo F, et al. Thrombospondin-1 and CD47 limit cell and tissue survival of radiation injury. Am J Pathol 2008;173:1100-12
46. Maxhimer JB, Soto-Pantoja DR, Ridnour LA, et al. Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling. Sci Transl Med 2009;1:3ra7
47. Soto-Pantoja DR, Miller TW, Pendrak ML, et al. CD47 deficiency confers cell and tissue radioprotection by activation of autophagy. Autophagy 2012; In press . Demonstrated that autophagy mediates the radipoprotective activity of CD47 blockade in healthy cells.
48. Kang R, Zeh HJ, Lotze MT, et al. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ 2011;18:571-80
49. Pan S. Molecular mechanisms responsible for the atheroprotective effects of laminar shear stress. Antioxid Redox Signal 2009;11:1669-82
50. Ignarro LJ. Nitric oxide as a unique signaling molecule in the vascular system: A historical overview. J Physiol Pharmacol 2002;53:503-14 (Pubitemid 36014797)
51. Chung J, Wang XQ, Lindberg FP, et al. Thrombospondin-1 acts via IAP/ CD47 to synergize with collagen in alpha2beta1-mediated platelet activation. Blood 1999;94:642-8 (Pubitemid 29323878)
52. Albanyan AM, Harrison P, Murphy MF. Markers of platelet activation and apoptosis during storage of apheresisand buffy coat-derived platelet concentrates for 7 days. Transfusion 2009;49:108-17
53. Guo YL, Liu DQ, Bian Z, et al. Down-regulation of platelet surfaceCD47 expression in Escherichia coli O157:H7 infection-induced thrombocytopenia. PLoS One 2009;4:e7131
54. Wang X, Frazier WA. The thrombospondin receptor CD47 (IAP) modulates and associates with alpha2beta1 integrin in vascular smooth muscle cells. Mol Biol Cell 1998;9:865-74 (Pubitemid 28173639)
55. Freyberg MA, Kaiser D, Graf R, et al. Proatherogenic flow conditions initiate endothelial apoptosis via thrombospondin-1 and the integrin-associated protein. Biochem Biophys Res Commun 2001;286:141-9 (Pubitemid 32917661)
56. Sajid M, Hu Z, Guo H, et al. Vascular expression of integrin-associated protein and thrombospondin increase after mechanical injury. J Investig Med 2001;49:398-406 (Pubitemid 32777003)
57. Isenberg JS, Annis DS, Pendrak ML, et al. Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses. J Biol Chem 2009;284:1116-25
58. Kanda S, Shono T, Tomasini-Johansson B, et al. Role of thrombospondin-1-derived peptide, 4N1K, in FGF-2-induced angiogenesis. Exp Cell Res 1999;252:262-72 (Pubitemid 29530257)
59. Isenberg JS, Ridnour LA, Perruccio EM, et al. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci USA 2005;102:13141-6 (Pubitemid 41324992)
60. Isenberg JS, Pappan LK, Romeo MJ, et al. Blockade of thrombospondin-1- CD47 interactions prevents necrosis of full thickness skin grafts. Ann Surg 2008;247:180-90
61. Hausman MR, Rinker BD. Intractable wounds and infections: The role of impaired vascularity and advanced surgical methods for treatment. Am J Surg 2004;187:44S-55S (Pubitemid 38625988)
62. Xing C, Lee S, Kim WJ, et al. Neurovascular effects of CD47 signaling: promotion of cell death, inflammation, and suppression of angiogenesis in brain endothelial cells in vitro. J Neurosci Res 2009;87:2571-7
63. Isenberg JS, Maxhimer JB, Powers P, et al. Treatment of ischemia/reperfusion injury by limiting thrombospondin-1/ CD47 ignaling. Surgery 2008;144:752-61
64. Isenberg JS, Hyodo F, Matsumoto K, et al. Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. Blood 2007;109:1945-52 (Pubitemid 46348191)
65. Isenberg JS, Romeo MJ, Abu-Asab M, et al. Increasing survival of ischemic tissue by targeting CD47. Circ Res 2007;100:712-20 (Pubitemid 46594886)
66. Maile LA, Allen LB, Hanzaker CF, et al. Glucose regulation of thrombospondin and its role in the modulation of smooth muscle cell proliferation. Exp Diabetes Res 2010;2010
67. Maxhimer JB, Shih HB, Isenberg JS, et al. Thrombospondin-1- CD47 blockade following ischemia reperfusion injury is tissue protective. Plast Reconstr Surg 2009;124:1880-9
68. Hart EC, Charkoudian N. Sympathetic neural mechanisms in human blood pressure regulation. Curr Hypertens Rep 2011;13:237-43
69. Singh M, Mensah GA, Bakris G. Pathogenesis and clinical physiology of hypertension. Cardiol Clin 2010;28:545-59
70. Forstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J 2012;33:829-37; 837a-837d
71. Curwen JO, Musgrove HL, Kendrew J, et al. Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy. Clin Cancer Res 2008;14:3124-31
72. Isenberg JS, Qin Y, Maxhimer JB, et al. Thrombospondin-1 and CD47 regulate blood pressure and cardiac responses to vasoactive stress. Matrix Biol 2009;28:110-19
73. Ochoa CD, Yu L, Al-Ansari E, et al. Thrombospondin-1 null mice are resistant to hypoxia-induced pulmonary hypertension. J Cardiothorac Surg 2010;5:32
74. Chaulet H, Lin F, Guo J, et al. Sustained augmentation of cardiac alpha1A-adrenergic drive results in pathological remodeling with contractile dysfunction, progressive fibrosis and reactivation of matricellular protein genes. J Mol Cell Cardiol 2006;40:540-52
75. Lindberg FP, Bullard DC, Caver TE, et al. Decreased resistance to bacterial infection and granulocyte defects in IAP-deficient mice. Science 1996;274:795-8 (Pubitemid 26398263)
76. Herold S, von Wulffen W, Steinmueller M, et al. Alveolar epithelial cells direct monocyte transepithelial migration upon influenza virus infection: impact of chemokines and adhesion molecules. J Immunol 2006;177:1817-24 (Pubitemid 44092519)
77. Azcutia V, Stefanidakis M, Tsuboi N, et al. Endothelial CD47 Promotes Vascular Endothelial-Cadherin Tyrosine Phosphorylation and Participates in T Cell Recruitment at Sites of Inflammation In Vivo. J Immunol 2012;189(5):2553-62
78. Chin AC, Fournier B, Peatman EJ, et al. CD47 and TLR-2 cross-talk regulates neutrophil transmigration. J Immunol 2009;183:5957-63
79. Van VQ, Lesage S, Bouguermouh S, et al. Expression of the self-marker CD47 on dendritic cells governs their trafficking to secondary lymphoid organs. EMBO J 2006;25:5560-8 (Pubitemid 44847196)
80. Li Z, Calzada MJ, Sipes JM, et al. Interactions of thrombospondins with alpha4beta1 integrin and CD47 differentially modulate T cell behavior. J Cell Biol 2002;157:509-19 (Pubitemid 34839813)
81. Matozaki T, Murata Y, Okazawa H, et al. Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway. Trends Cell Biol 2009;19:72-80
82. Blazar BR, Lindberg FP, Ingulli E, et al. CD47 (integrin-associated protein) engagement of dendritic cell and macrophage counterreceptors is required to prevent the clearance of donorlymphohematopoietic cells. J Exp Med 2001;194:541-9 (Pubitemid 32835048)
83. Wang C, Wang H, Ide K, et al. Human CD47 expression permits survival of porcine cells in immunodeficient mice that express. SIRPalpha capable of binding to human CD47. Cell Transplant 2011; [Epub ahead of print] . Describes a strategy using CD47 expression to overcome a barrier to xenotransplantion.
84. Ide K, Wang H, Tahara H, et al. Role for CD47-SIRPalpha signaling in xenograft rejection by macrophages. Proc Natl Acad Sci USA 2007;104:5062-6 (Pubitemid 47186176)
85. Wang H, Madariaga ML, Wang S, et al. Lack of CD47 on nonhematopoietic cells induces split macrophage tolerance to CD47null cells. Proc Natl Acad Sci USA 2007;104:13744-9 (Pubitemid 350003391)
86. Kim MJ, Lee JC, Lee JJ, et al. Association of CD47 with natural killer cell-mediated cytotoxicity of head-and-neck squamous cell carcinoma lines. Tumour Biol 2008;29:28-34 (Pubitemid 351733217)
87. Zhao XW, Kuijpers TW, van den Berg TK. Is targeting of CD47-SIRPalpha enough for treating hematopoietic malignancy? Blood 2012;119:4333-4; author reply 4334-5
88. Zhao XW, van Beek EM, Schornagel K, et al. CD47-signal regulatory protein-alpha (SIRPalpha) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci USA 2011;108:18342-7
89. Ticchioni M, Deckert M, Mary F, et al. Integrin-associated protein (CD47) is a comitogenic molecule on CD3-activated human T cells. J Immunol 1997;158:677-84 (Pubitemid 127492645)
90. Wilson KE, Li Z, Kara M, et al. beta1 integrin- and proteoglycan-mediated stimulation of T lymphoma cell adhesion and mitogen-activated protein kinase signaling by thrombospondin-1 and thrombospondin-1 peptides. J Immunol 1999;163:3621-8 (Pubitemid 29450882)
91. Li Z, He L, Wilson KE, et al. Thrombospondin-1 inhibits TCR-mediated T lymphocyte early activation. J Immunol 2001;166:2427-36 (Pubitemid 32173478)
92. Reinhold MI, Lindberg FP, Kersh GJ, et al. Costimulation of T cell activation by integrin-associated protein (CD47) is an adhesion-dependent, CD28-independent signaling pathway. J Exp Med 1997;185:1-11 (Pubitemid 27039436)
93. Reinhold MI, Green JM, Lindberg FP, et al. Cell spreading distinguishes the mechanism of augmentation of T cell activation by integrin-associated protein/CD47 and CD28. Int Immunol 1999;11:707-18 (Pubitemid 29237762)
94. Piccio L, Vermi W, Boles KS, et al. Adhesion of human T cells to antigen-presenting cells through SIRPbeta2-CD47 interaction costimulates T-cell proliferation. Blood 2005;105:2421-7 (Pubitemid 40387041)
95. O'Shea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 2010;327:1098-102
96. Latour S, Tanaka H, Demeure C, et al. Bidirectional negative regulation of human T and dendritic cells by CD47 and its cognate receptor signal-regulator protein-alpha: down-regulation of IL-12 responsiveness and inhibition of dendritic cell activation. J Immunol 2001;167:2547-54 (Pubitemid 32768881)
97. Avice MN, Rubio M, Sergerie M, et al. CD47 ligation selectively inhibits the development of human naive T cells into Th1 effectors. J Immunol 2000;165:4624-31
98. Bouguermouh S, Van VQ, Martel J, et al. CD47 expression on T cell is a self-control negative regulator of type 1 immune response. J Immunol 2008;180:8073-82
99. Lamy L, Foussat A, Brown EJ, et al. Interactions between CD47 and thrombospondin reduce inflammation. J Immunol 2007;178:5930-9 (Pubitemid 46674390)
100. Vallbo C, Damber JE. Thrombospondins, metallo proteases and thrombospondin receptors messenger RNA and protein expression in different tumour sublines of the Dunning prostate cancer model. Acta Oncol 2005;44:293-8 (Pubitemid 40904133)
101. Rendtlew Danielsen JM, Knudsen LM, Dahl IM, et al. Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma. Br J Haematol 2007;138:756-60 (Pubitemid 47313218)
102. Raetz EA, Perkins SL, Bhojwani D, et al. Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Pediatr Blood Cancer 2006;47:130-40 (Pubitemid 44025244)
103. Suhr ML, Dysvik B, Bruland O, et al. Gene expression profile of oral squamous cell carcinomas from Sri Lankan betel quid users. Oncol Rep 2007;18:1061-75
104. Chan KS, Espinosa I, Chao M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA 2009;106:14016-21
105. Nagahara M, Mimori K, Kataoka A, et al. Correlated expression of CD47 and SIRPA in bone marrow and in peripheral blood predicts recurrence in breast cancer patients. Clin Cancer Res 2010;16:4625-35
106. Sarfati M, Fortin G, Raymond M, et al. CD47 in the immune response: role of thrombospondin and SIRP-alpha reverse signaling. Curr Drug Targets 2008;9:842-50
107. Uluckan O, Becker SN, Deng H, et al. CD47 regulates bone mass and tumor metastasis to bone. Cancer Res 2009;69:3196-204
108. Martin-Manso G, Galli S, Ridnour LA, et al. Thrombospondin-1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity by differentiated U937 cells. Cancer Res 2008;68:7090-9
109. Jaiswal S, Chao MP, Majeti R, et al. Macrophages as mediators of tumor immunosurveillance. Trends Immunol 2010;31:212-19
110. Soto-Pantoja DR, Isenberg JS, Roberts DD. Therapeutic Targeting of CD47 to Modulate Tissue Responses to Ischemia and Radiation. J Genet Syndr Gene Ther 2011;2:1000105
111. Sick E, Jeanne A, Schneider C, et al. CD47 update: A multi-faceted actor in the tumour microenvironment of potential therapeutic interest. Br J Pharmacol 2012. [Epub Ahead of print]
112. Manna PP, Frazier WA. CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A. Cancer Res 2004;64:1026-36 (Pubitemid 38176906)
113. Rath GM, Schneider C, Dedieu S, et al. Thrombospondin-1 C-terminal-derived peptide protects thyroid cells from ceramide-induced apoptosis through the adenylyl cyclase pathway. Int J Biochem Cell Biol 2006;38:2219-28 (Pubitemid 44419501)
114. Soto-Pantoja DR, Miller TW, Pendrak ML, et al. CD47 deficiency confers cell and tissue radioprotection by activation of autophagy. Autophagy 2012;8; In press
115. Isenberg JS, Martin-Manso G, Maxhimer JB, et al. Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. Nat Rev Cancer 2009;9:182-94
116. Kaur S Roberts DD. CD47 applies the brakes to angiogenesis via vascular endothelial growth factor receptor-2. Cell Cycle 2011;10:10-12
117. Isenberg JS, Hyodo F, Ridnour LA, et al. Thrombospondin-1 and vasoactive agents indirectly alter tumor blood flow. Neoplasia 2008;10:886-96
118. Kukreja A, Radfar S, Sun BH, et al. Dominant role of CD47-thrombospondin- 1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease. Blood 2009;114:3413-21
119. Sagawa M, Shimizu T, Fukushima N, et al. A new disulfide-linked dimer of a single-chain antibody fragment against human CD47 induces apoptosis in lymphoid malignant cells via the hypoxia inducible factor-1alpha pathway. Cancer Sci 2011;102:1208-15
120. Isenberg JS, Romeo MJ, Maxhimer JB, et al. Gene silencing of CD47 and antibody ligation of thrombospondin-1 enhance ischemic tissue survival in a porcine model: implications for human disease.b Ann Surg 2008;247:860-8
121. van Ravenswaay Claasen HH, Eggermont AM, Nooyen YA, et al. Immunotherapy in a human ovarian cancer xenograft model with two bispecific monoclonal antibodies: OV-TL 3/CD3 and OC/TR. Gynecol Oncol 1994;52:199-206 (Pubitemid 24064370)
122. Chao MP, Alizadeh AA, Tang C, et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res 2011;71:1374-84
123. Haviv F, Bradley MF, Kalvin DM, et al. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. J Med Chem 2005;48:2838-46
124. Henkin J, Volpert OV. Therapies using anti-angiogenic peptide mimetics of thrombospondin-1. Expert Opin Ther Targets 2011;15:1369-86
125. Fortin G, Raymond M, Van VQ, et al. A role for CD47 in the development of experimental colitis mediated by SIRPalpha+CD103- dendritic cells. J Exp Med 2009;206:1995-2011
126. Finley MJ, Rauova L, Alferiev IS, et al. Diminished adhesion and activation of platelets and neutrophils with CD47 functionalized blood contacting surfaces. Biomaterials 2012;33:5803-11
127. Raymond M, Van VQ, Rubio M, et al. Targeting SIRP-alpha protects from type 2-driven allergic airway inflammation. Eur J Immunol 2010;40:3510-18
128. Yu X, Fukunaga A, Nagai H, et al. Engagement of CD47 inhibits the contact hypersensitivity response via the suppression of motility and B7 expression by Langerhans cells. J Invest Dermatol 2006;126:797-807
129. Fukunaga A, Nagai H, Noguchi T, et al. Src homology 2 domain-containing protein tyrosine phosphatase substrate 1 regulates the migration of Langerhans cells from the epidermis to draining lymph nodes. J Immunol 2004;172:4091-9 (Pubitemid 38375221)
130. Han MH, Lundgren DH, Jaiswal S, et al. Janus-like opposing roles of CD47 in autoimmune brain inflammation in humans and mice. J Exp Med 2012;209:1325-34
131. Kikuchi Y, Uno S, Kinoshita Y, et al. Apoptosis inducing bivalent single-chain antibody fragments against
132. CD47 showed antitumor potency for multiple myeloma. Leuk Res 2005;29:445-50
133. Chao MP, Alizadeh AA, Tang C, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 2010;142:699-713
134. Chao MP, Tang C, Pachynski RK, et al. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood 2011;118:4890-901
135. Kim D, Wang J, Willingham SB, et al. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia 2012
136. Soto-Pantoja DR, Miller TW, Frazier WA, et al. Inhibitory signaling through signal regulatory protein-alpha is not sufficient to explain the antitumor activities of CD47 antibodies. Proc Natl Acad Sci USA 2012; In press
137. Zhao XW, Matlung HL, Kuijpers TW, et al. On the mechanism of CD47 targeting in cancer. Proc Natl Acad Sci USA 2012; In press
138. Olsson M, Bruhns P, Frazier WA, et al. Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. Blood 2005;105:3577-82 (Pubitemid 40628203)
139. Chung J, Gao AG, Frazier WA. Thrombspondin acts via integrin-associated protein to activate the platelet integrin alphaIIbbeta3. J Biol Chem 1997;272:14740-6 (Pubitemid 27251740)
140. Subramanian S, Parthasarathy R, Sen S, et al. Species- and cell type-specific interactions between CD47 and human SIRPalpha. Blood 2006;107:2548-56 (Pubitemid 43348703)
141. Cirak S, Arechavala-Gomeza V, Guglieri M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study. Lancet 2011;378(9791):595-605